Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
γδ TCR modulator
DRUG CLASS:
γδ TCR modulator
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
ACE2016 (2)
ADI-001 (1)
ACE1831 (0)
ADI-002 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CD7-UCAR-γδT cells (0)
CLN-619 (0)
CTM-N2D (0)
ECT204 (0)
ET 019003 (0)
ET-190 (0)
ET140203 (0)
ET1402L1-ARTEMIS T cells (0)
ET206 (0)
GDT002 (0)
Gamma delta T-cells (0)
ICT01 (0)
INB-100 (0)
INB-200 (0)
INB-300 (0)
autologous γδ T lymphocytes (0)
ALEXIS-ISO-1 (0)
LAVA-051 (0)
LYT-210 (0)
NK/γδ T cell-enriched cell therapy (0)
PF-08046052 (0)
QH104 (0)
TAK-012 (0)
UTAA06 (0)
anti-CD19-CAR γδT (0)
AVM0703 (0)
γδT Cell infusion (0)
γδT Cell infusion agent (0)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
ACE2016 (2)
ADI-001 (1)
ACE1831 (0)
ADI-002 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CD7-UCAR-γδT cells (0)
CLN-619 (0)
CTM-N2D (0)
ECT204 (0)
ET 019003 (0)
ET-190 (0)
ET140203 (0)
ET1402L1-ARTEMIS T cells (0)
ET206 (0)
GDT002 (0)
Gamma delta T-cells (0)
ICT01 (0)
INB-100 (0)
INB-200 (0)
INB-300 (0)
autologous γδ T lymphocytes (0)
ALEXIS-ISO-1 (0)
LAVA-051 (0)
LYT-210 (0)
NK/γδ T cell-enriched cell therapy (0)
PF-08046052 (0)
QH104 (0)
TAK-012 (0)
UTAA06 (0)
anti-CD19-CAR γδT (0)
AVM0703 (0)
γδT Cell infusion (0)
γδT Cell infusion agent (0)
›
Associations
(7)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of SGN-EGFRd2 in Advanced Solid Tumors (SGNEGFRd2-001) (NCT05983133)
Phase 1
Seagen Inc.
Seagen Inc.
Recruiting
Phase 1
Seagen Inc.
Recruiting
Last update posted :
02/20/2025
Initiation :
11/14/2023
Primary completion :
07/31/2027
Completion :
09/30/2028
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement
|
PF-08046052
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
Phase 1/2
Chinese PLA General Hospital
Chinese PLA General Hospital
Recruiting
Phase 1/2
Chinese PLA General Hospital
Recruiting
Last update posted :
02/19/2025
Initiation :
12/11/2022
Primary completion :
12/31/2026
Completion :
12/31/2027
BCL2 • CCND1 • BCL6
|
CD19 positive • Chr t(11;14)
|
cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (CLN-619-001) (NCT05117476)
Phase 1
Cullinan Therapeutics Inc.
Cullinan Therapeutics Inc.
Recruiting
Phase 1
Cullinan Therapeutics Inc.
Recruiting
Last update posted :
02/03/2025
Initiation :
10/29/2021
Primary completion :
03/01/2026
Completion :
06/01/2026
EGFR • ALK
|
Keytruda (pembrolizumab) • CLN-619
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) (NCT06415487)
Phase 1
Acepodia Biotech, Inc.
Acepodia Biotech, Inc.
Not yet recruiting
Phase 1
Acepodia Biotech, Inc.
Not yet recruiting
Last update posted :
05/15/2024
Initiation :
05/31/2024
Primary completion :
12/18/2026
Completion :
03/25/2027
IL2
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA3) (NCT04864054)
Phase 2
Eureka Therapeutics Inc.
Eureka Therapeutics Inc.
Recruiting
Phase 2
Eureka Therapeutics Inc.
Recruiting
Last update posted :
05/06/2024
Initiation :
03/11/2022
Primary completion :
12/31/2026
Completion :
12/31/2026
GPC3
|
GPC3 expression • GPC3 positive
|
cyclophosphamide • Stivarga (regorafenib) • ECT204
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC (NCT06193486)
Phase 1
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Resear...
Recruiting
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Recruiting
Last update posted :
03/13/2024
Initiation :
02/26/2024
Primary completion :
01/13/2029
Completion :
12/13/2033
PSCA
|
cyclophosphamide • fludarabine IV
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) (NCT04634357)
Phase 1/2
Eureka Therapeutics Inc.
Eureka Therapeutics Inc.
Recruiting
Phase 1/2
Eureka Therapeutics Inc.
Recruiting
Last update posted :
03/07/2024
Initiation :
07/19/2022
Primary completion :
01/31/2026
Completion :
01/31/2028
AFP
|
ET140203
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (NCT05653271)
Phase 1
Acepodia Biotech, Inc.
Acepodia Biotech, Inc.
Recruiting
Phase 1
Acepodia Biotech, Inc.
Recruiting
Last update posted :
02/28/2024
Initiation :
01/21/2023
Primary completion :
09/01/2025
Completion :
09/01/2027
CD20 • IFNG • IL6 • TNFA • IL2 • IL10
|
CD20 positive
|
Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC (NCT06069570)
Phase 1
Kiromic BioPharma Inc.
Kiromic BioPharma Inc.
Recruiting
Phase 1
Kiromic BioPharma Inc.
Recruiting
Last update posted :
12/15/2023
Initiation :
11/07/2023
Primary completion :
10/01/2024
Completion :
01/01/2027
EGFR • KRAS • BRAF • ALK • ROS1
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (NCT06056752)
Phase 1
Anhui Provincial Hospital
Anhui Provincial Hospital
Recruiting
Phase 1
Anhui Provincial Hospital
Recruiting
Last update posted :
10/24/2023
Initiation :
09/27/2023
Primary completion :
07/03/2025
Completion :
07/03/2026
IL6 • TNFA • IL2 • IL10
|
CD19 positive
|
cyclophosphamide • fludarabine IV
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (NCT06092047)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co.,...
Not yet recruiting
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Not yet recruiting
Last update posted :
10/20/2023
Initiation :
10/01/2023
Primary completion :
07/01/2026
Completion :
04/01/2028
IL6
|
CD19 positive
|
cyclophosphamide • fludarabine IV
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (NCT06018363)
Phase 1/2
Dushu Lake Hospital Affiliated to Soochow University
Dushu Lake Hospital Affiliated to Sooch...
Recruiting
Phase 1/2
Dushu Lake Hospital Affiliated to Soochow Unive...
Recruiting
Last update posted :
08/30/2023
Initiation :
06/01/2023
Primary completion :
12/31/2025
Completion :
12/31/2026
IL6 • CD276 • IL10
|
CD276 expression
|
QH104
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05731219)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co.,...
Recruiting
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recruiting
Last update posted :
02/16/2023
Initiation :
09/26/2022
Primary completion :
09/26/2023
Completion :
09/26/2025
CD276
|
CD276 expression
|
UTAA06
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05722171)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co.,...
Recruiting
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recruiting
Last update posted :
02/10/2023
Initiation :
12/27/2022
Primary completion :
12/27/2023
Completion :
12/27/2024
CD276
|
CD276 expression
|
UTAA06
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (NCT04688853)
Phase 1
Gadeta B.V.
Gadeta B.V.
Active, not recruiting
Phase 1
Gadeta B.V.
Active, not recruiting
Last update posted :
09/08/2022
Initiation :
05/13/2021
Primary completion :
07/30/2023
Completion :
07/30/2024
IL6
|
GDT002
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (NCT05302037)
Phase 1
CytoMed Therapeutics Pte Ltd
CytoMed Therapeutics Pte Ltd
Not yet recruiting
Phase 1
CytoMed Therapeutics Pte Ltd
Not yet recruiting
Last update posted :
03/31/2022
Initiation :
04/01/2022
Primary completion :
03/01/2023
Completion :
12/01/2023
NKG2D
|
CTM-N2D
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma (NCT03888859)
Phase 1
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital Xi'an Jiaoton...
Completed
Phase 1
First Affiliated Hospital Xi'an Jiaotong Univer...
Completed
Last update posted :
03/29/2021
Initiation :
12/06/2017
Primary completion :
04/13/2019
Completion :
12/08/2020
HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4
|
HLA-A*02 • AFP expression
|
ET1402L1-ARTEMIS T cells
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors (NCT04702841)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co.,...
Recruiting
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recruiting
Last update posted :
03/08/2021
Initiation :
06/03/2020
Primary completion :
06/01/2022
Completion :
12/01/2022
CD7
|
CD7-UCAR-γδT cells • γδT Cell infusion • γδT Cell infusion agent
ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer (NCT03965546)
Phase 1
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital Xi'an Jiaoton...
Unknown status
Phase 1
First Affiliated Hospital Xi'an Jiaotong Univer...
Unknown status
Last update posted :
08/08/2019
Initiation :
05/30/2019
Primary completion :
06/01/2021
Completion :
06/01/2022
HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10
|
HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression
|
sorafenib • ET1402L1-ARTEMIS T cells
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL (NCT02656147)
Phase 1
Beijing Doing Biomedical Co., Ltd.
Beijing Doing Biomedical Co., Ltd.
Unknown status
Phase 1
Beijing Doing Biomedical Co., Ltd.
Unknown status
Last update posted :
09/05/2017
Initiation :
10/01/2017
Primary completion :
04/01/2019
Completion :
04/01/2020
CD19
|
CD19 expression
|
Gamma delta T-cells • anti-CD19-CAR γδT
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login